840
Participants
Start Date
September 30, 2011
Primary Completion Date
June 30, 2015
Study Completion Date
June 30, 2015
Arbidol (Umifenovir)
Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
placebo
Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
Arbidol (Umifenovir)
Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
placebo
Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
NOT_YET_RECRUITING
Research Institute of Influenza, Saint Petersburg
RECRUITING
Saratov
Lead Sponsor
Pharmstandard
INDUSTRY